poisar

Stocks · News reference

Evaxion Reports Phase II Results for EVX-01 in Advanced Melanoma

Evaxion Biotech announced that its Phase II study of EVX-01 in combination with pembrolizumab demonstrated a 75% objective response rate in patients with advanced melanoma.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

EVAX
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Evaxion A/S

    New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

    Evaxion announced new phase 2 biomarker data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating potent neoantigen-specific T-cell responses and validating the predictive performance of its AI-Immunology™ platform. The data showed 89% vaccine target precision with sustained clinical responses at three-year follow-up, including a 75% objective response rate at two years.

    EVAXMRK
  6. Na

    Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

    Evaxion A/S, a clinical-stage TechBio company, has won the 2026 International Prix Galien Award for its AI-Immunology platform as the best digital health solution, marking the first time a Danish company has received this prestigious award. The recognition follows positive three-year phase 2 trial data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, which demonstrated 89% vaccine target precision and sustained T-cell responses.

    EVAX